Piper Sandler Reaffirms Optimism on Compass Therapeutics (CMPX) Amid Trial Update
Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the must-buy penny stocks to invest in.
Compass Therapeutics Inc. (CMPX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | OrbiMed Advisors Samuel Isaly | 15,219,994 | $39,571,984 | -32% | 0.99% |
| 2. | Tang Capital Management Kevin C. Tang | 13,496,208 | $35,090,141 | +23% | 1.77% |
| 3. | Enavate Sciences James Boylan | 7,788,150 | $20,249,190 | 11.47% | |
| 4. | Suvretta Capital Management Aaron Cowen | 7,149,493 | $18,588,682 | 0.56% | |
| 5. | Vivo Capital Albert Cha And Frank Kung | 6,043,466 | $15,713,012 | +70% | 1.61% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.11 | 10,000 | $21,100.00 | 6,480,825 | 2025-05-27 | Filing | |
| $1.54 | 20,000 | $30,800.00 | 21,000 | 2025-04-07 | Filing | |
| $1.42 | 20,000 | $28,400.00 | 320,000 | 2025-04-07 | Filing | |
| $3.37 | 10,000 | $33,700.00 | 6,021,873 | 2023-03-10 | Filing | |
| $3.98 | 20,000 | $79,600.00 | 6,011,873 | 2023-02-27 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.59 | 3,571,428 | $5,678,570.52 | 0 | 2025-04-09 | Filing | |
| $1.59 | 3,571,428 | $5,678,570.52 | 0 | 2025-04-09 | Filing | |
| $4.36 | 2 | $8.72 | 1,060,414 | 2022-11-25 | Filing | |
| $4.30 | 9,569 | $41,146.70 | 1,060,416 | 2022-11-23 | Filing | |
| $4.19 | 14,929 | $62,552.51 | 1,069,985 | 2022-11-22 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,025,151 | $26,065,393 | 0.11% | |
| 2. | 6,413,133 | $16,674,146 | 0% | |
| 3. | 4,850,005 | $12,610,013 | 0% | |
| 4. | 4,134,655 | $10,750,103 | 0% | |
| 5. | 2,591,525 | $6,737,965 | 2.17% |
News See All
10 Must-Buy Penny Stocks to Invest In
According to the LSEG 2025 Mid-Year Outlook, small-cap earnings are projected to grow 40.8% in 2025, compared to 8.8% for the S&P 500.
Compass Therapeutics (CMPX) Rated ‘Outperform’ amid Clinical Pipeline Development
Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the top multibagger penny stocks to buy, according to analysts.
13 Best Multibagger Penny Stocks to Buy According to Analysts
It’s time to pivot towards micro and small-cap stocks as the US Federal Reserve prepares to cut interest rates.
10 Best Performing Penny Stocks So Far in 2025
By midday Wednesday, July 23, 2025, the Russell 2000 was up 1.57% for the week. This compares to a 0.9% gain for the S&P 500.
Compass Therapeutics (CMPX) Gains Analyst Confidence with Promising Cancer Pipeline
Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the top high-return penny stocks to buy now. On July 14, Stifel reiterated its Buy rating and $11.00 price target for CMPX.
11 Best High Return Penny Stocks to Buy Now
US equity markets are back at all-time highs amid a muted response to new U.S. tariffs and the trade war. The Nasdaq Composite Index, performing relatively well among major U.S.
10 Hot Biotech Stocks Under $5
The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025
No matter the market environment, you’ll always find entertainment in the biotech space.
Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025
The healthcare sector is staging a comeback so far in 2025 after two years of underperformance. These stocks could get even hotter due to AI.
Billionaire Hedge Funds
